Immunic Inc (IMUX) - Net Assets
Based on the latest financial reports, Immunic Inc (IMUX) has net assets worth $-6.67 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($24.05 Million) and total liabilities ($30.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Immunic Inc (IMUX) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.67 Million |
| % of Total Assets | -27.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | -105.25% |
| 10-Year Change | -111.42% |
| Growth Volatility | 132.8 |
Immunic Inc - Net Assets Trend (2011–2025)
This chart illustrates how Immunic Inc's net assets have evolved over time, based on quarterly financial data. Also explore IMUX total asset value for the complete picture of this company's asset base.
Annual Net Assets for Immunic Inc (2011–2025)
The table below shows the annual net assets of Immunic Inc from 2011 to 2025. For live valuation and market cap data, see Immunic Inc (IMUX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-6.67 Million | -136.21% |
| 2024-12-31 | $18.43 Million | -36.30% |
| 2023-12-31 | $28.93 Million | -74.55% |
| 2022-12-31 | $113.68 Million | -10.57% |
| 2021-12-31 | $127.11 Million | -19.95% |
| 2020-12-31 | $158.78 Million | +172.06% |
| 2019-12-31 | $58.36 Million | +369.65% |
| 2018-12-31 | $12.43 Million | -75.17% |
| 2017-12-31 | $50.04 Million | -14.38% |
| 2016-12-31 | $58.45 Million | -29.01% |
| 2015-12-31 | $82.33 Million | -15.62% |
| 2014-12-31 | $97.56 Million | +135.56% |
| 2013-12-31 | $41.42 Million | +642.69% |
| 2012-12-31 | $-7.63 Million | +86.09% |
| 2011-12-31 | $-54.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunic Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 54482400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | % |
| Other Comprehensive Income | $2.65 Million | % |
| Other Components | $599.24 Million | % |
| Total Equity | $-6.67 Million | 100.00% |
Immunic Inc Competitors by Market Cap
The table below lists competitors of Immunic Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Precision Camshafts Limited
NSE:PRECAM
|
$163.09 Million |
|
Adairs Ltd
AU:ADH
|
$163.12 Million |
|
Samart Corporation Public Company Limited
BK:SAMART
|
$163.13 Million |
|
Cyberlink Co
TW:5203
|
$163.15 Million |
|
Shenyang Cuihua Gold and Silver Jewelry Co Ltd
SHE:002731
|
$163.05 Million |
|
Eightco Holdings Inc.
NASDAQ:ORBS
|
$163.01 Million |
|
Vivozon Healthcare Inc
KQ:082800
|
$162.99 Million |
|
Empresas Iansa S.A
SN:IANSA
|
$162.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunic Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,429,000 to -6,673,000, a change of -25,102,000 (-136.2%).
- Net loss of 97,172,000 reduced equity.
- Share repurchases of 182,000 reduced equity.
- New share issuances of 65,395,000 increased equity.
- Other comprehensive income decreased equity by 1,561,000.
- Other factors increased equity by 8,418,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-97.17 Million | -1456.2% |
| Share Repurchases | $182.00K | -2.73% |
| Share Issuances | $65.39 Million | +979.99% |
| Other Comprehensive Income | $-1.56 Million | -23.39% |
| Other Changes | $8.42 Million | +126.15% |
| Total Change | $- | -136.21% |
Book Value vs Market Value Analysis
This analysis compares Immunic Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-3889.18 | $9.65 | x |
| 2012-12-31 | $-541.12 | $9.65 | x |
| 2013-12-31 | $2936.61 | $9.65 | x |
| 2014-12-31 | $163.76 | $9.65 | x |
| 2015-12-31 | $130.92 | $9.65 | x |
| 2016-12-31 | $74.48 | $9.65 | x |
| 2017-12-31 | $50.22 | $9.65 | x |
| 2018-12-31 | $11.73 | $9.65 | x |
| 2019-12-31 | $7.56 | $9.65 | x |
| 2020-12-31 | $10.14 | $9.65 | x |
| 2021-12-31 | $5.37 | $9.65 | x |
| 2022-12-31 | $3.57 | $9.65 | x |
| 2023-12-31 | $0.65 | $9.65 | x |
| 2024-12-31 | $0.18 | $9.65 | x |
| 2025-12-31 | $0.00 | $9.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunic Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-122.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-393.70K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.94 Million |
| 2013 | -78.99% | 0.00% | 0.00x | 1.12x | $-36.86 Million |
| 2014 | -48.86% | 0.00% | 0.00x | 1.11x | $-57.42 Million |
| 2015 | -63.19% | 0.00% | 0.00x | 1.08x | $-60.26 Million |
| 2016 | -70.10% | -682816.67% | 0.00x | 1.10x | $-46.81 Million |
| 2017 | -104.06% | 0.00% | 0.00x | 1.21x | $-57.08 Million |
| 2018 | -333.75% | 0.00% | 0.00x | 1.21x | $-42.72 Million |
| 2019 | -59.67% | 0.00% | 0.00x | 1.13x | $-40.66 Million |
| 2020 | -27.72% | 0.00% | 0.00x | 1.06x | $-59.90 Million |
| 2021 | -73.00% | 0.00% | 0.00x | 1.09x | $-105.51 Million |
| 2022 | -105.91% | 0.00% | 0.00x | 1.12x | $-131.78 Million |
| 2023 | -323.57% | 0.00% | 0.00x | 1.88x | $-96.51 Million |
| 2024 | -545.37% | 0.00% | 0.00x | 2.22x | $-102.35 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-96.50 Million |
Industry Comparison
This section compares Immunic Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunic Inc (IMUX) | $-6.67 Million | 0.00% | N/A | $163.08 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more